Novartis | NOVN - Beban Penjualan Dan Administrasi





Beban Penjualan Dan Administrasi Perubahan Tanggal
AbbVie USD 3.89B 325M 2025-12
Alcon AG USD 901M 36M 2025-12
Amgen USD 1.94B 237M 2025-12
AstraZeneca USD 4.61B 4.46B 2025-12
Autolus Therapeutics Ltd USD 35.79M 1.68M 2025-12
Bayer EUR 4.05B 647M 2025-12
Biogen USD 545.2M 38.6M 2025-09
Bristol-Myers Squibb USD 2.18B 392M 2025-12
Eli Lilly USD 3.13B 391.3M 2025-12
Fresenius EUR 819M 143M 2025-12
Fresenius Medical Care EUR 785M 79.56M 2025-12
Galapagos EUR 44.42M 9.87M 2025-12
Genmab DKK 208M 60M 2025-12
Gilead Sciences USD 1.78B 425M 2025-12
GlaxoSmithKline GBP 2.68B 518M 2025-12
GRIFOLS EUR 275.3M 9.7M 2025-12
Hikma Pharmaceutical USD 288M 149M 2025-12
J&J USD 6.75B 831M 2025-12
Merck EUR 1.6B 136M 2025-12
Merck USD 2.85B 215M 2025-12
Novartis USD 3.44B 128M 2025-12
Novartis USD 3.44B 132M 2025-12
Novo Nordisk DKK 17.44B 1.41B 2025-12
Orion EUR 110.7M 26.1M 2025-12
Pfizer USD 4.08B 894M 2025-12
Philips EUR 1.31B 127M 2025-12
Recordati EUR 171.38M 15.6M 2025-09
Regeneron Pharmaceuticals USD 775M 117.2M 2025-12
Roche Holding CHF 7.28B 3.99B 2025-12
Sanofi EUR 2.75B 455M 2025-12
UCB EUR 1.47B 193M 2025-12